Zydus Cadila launches biosimilar Ujvira

Zydus Cadila is introducing Ujvira, the first antibody drug conjugate biosimilar of trastuzumab emtansine. The drug is used for treating both early and advanced HER2-positive breast cancer. 

HER2-positive breast cancer is considered an aggressive form and constitutes 20 to 25% of all breast cancers. 

Ujvira will be available in two strengths, 100 mg and 160 mg.

“The launch of Ujvira reinforces the innovation capabilities that India has to be able to create complex therapies like ADCs and Zydus' ongoing commitment to offer breakthroughs backed by science and innovation. This research breakthrough enables access to a critical drug for patients who are undergoing therapy for breast cancer. We hope that with this innovation, patients will be able to adhere to the treatment and stand to benefit from the advanced technology without worrying about the cost of the treatment,” Cadila Healthcare managing director Sharvil Patel said.